港股異動 | 再鼎醫藥漲22% 獲摩通增持 股份除“B”
格隆匯11月14日丨再鼎醫藥(9688.HK)漲22.75%,報29.95港元,總市值293億港元。根據聯交所最新權益披露資料顯示,2022年11月7日,再鼎醫藥獲JPMorgan Chase & Co.以每股均價24.7812港元增持好倉1144.52萬股,涉資約2.84億港元。增持後,JPMorgan Chase & Co.最新持好倉數目為5694.84萬股,持好倉比例由4.64%上升至5.81%。同日,FMR LLC增持再鼎醫藥362.3651萬股,每股作價25.6282港元,總金額約為9286.77萬港元。增持後最新持股數目約1.00億股,最新持股比例為10.26%。另外,公司宣佈,因公司已滿足根據第18A章以外之規則上市所適用的收益和市值要求,聯交所證券上市規則第18A.12條提出申請後,香港聯合交易所已批准公司不適用生物科技章節上市規則18A.09至18A.11條。因此,自2022年11月11日起,公司中英文股份簡稱將不再加上標記“B”。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.